Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This is a Prospective, Single-arm, Multicenter, Observational Non-interventional Study (NIS) in Germany of Patient Characteristics, Usage, and Effectiveness of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT05250115 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05250115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05250115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This is a Prospective, Single-arm, Multicenter, Observational Non-interventional Study (NIS) in Germany of Patient Characteristics, Usage, and Effectiveness of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis (AD)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Terminated
Start date
May 10, 2022
Completion date
July 25, 2024
Enrollment
112 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic